文献速递冠心病

1型糖尿病多支病变:PCI与CABG的生存获益比较

PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease.
PubMed 文献 · J Am Coll Cardiol · 2017-08-26

该观察性队列研究纳入瑞典1995至2013年首次多支血管血运重建的1型糖尿病患者,比较PCI与CABG的长期结局。中位随访10.6年,PCI与CABG全因死亡风险相似,但PCI的冠心病死亡、心肌梗死和再次血运重建风险更高。提示CABG可能是此类患者的优选策略。

要点

  • 1型糖尿病多支病变患者中,PCI与CABG的全因死亡风险相似(HR 1.14,95%CI 0.99-1.32)。
  • PCI较CABG的冠心病死亡(HR 1.45)、心肌梗死(HR 1.47)和再次血运重建(HR 5.64)风险更高。
  • 两组卒中与心力衰竭风险无差异,CABG可能是1型糖尿病多支病变的优选策略。

核心结论

  • 在1型糖尿病需多支血管血运重建的患者中,PCI较CABG与更高的冠心病死亡、心肌梗死和再次血运重建风险相关,CABG可能是优选策略。

研究设计与样本

  • 观察性队列研究,纳入瑞典1995至2013年首次多支血管血运重建的1型糖尿病患者,CABG组683例,PCI组1863例。
  • 使用SWEDEHEART、瑞典国家糖尿病登记和瑞典国家患者登记获取患者特征与结局,采用基于倾向评分的逆概率治疗加权校正混杂因素。

主要发现

  • 平均随访10.6年,CABG组53%、PCI组45%的患者死亡。
  • PCI较CABG的全因死亡风险相似(HR 1.14;95%CI 0.99-1.32)。
  • PCI较CABG的冠心病死亡风险更高(HR 1.45;95%CI 1.21-1.74)。
  • PCI较CABG的心肌梗死风险更高(HR 1.47;95%CI 1.23-1.78)。
  • PCI较CABG的再次血运重建风险更高(HR 5.64;95%CI 4.67-6.82),卒中与心力衰竭风险无差异。

临床怎么用

  • 对1型糖尿病合并多支血管病变需血运重建者,应将CABG作为优先考虑的策略并与患者充分讨论。
  • 若选择PCI,需预期更高的冠心病死亡、心肌梗死和再次血运重建风险并加强随访。

局限性

  • 为观察性队列研究,即使采用倾向评分加权仍可能存在残余混杂。
  • PCI组可能纳入无法耐受CABG的1型糖尿病患者,存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unknown if coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) may offer a survival benefit in patients with type 1 diabetes (T1D) in need of multivessel revascularization. OBJECTIVES: This study sought to determine if patients with T1D and multivessel disease may benefit from CABG compared with PCI. METHODS: In an observational cohort study, the authors included all patients with T1D who underwent a first multivessel revascularization in Sweden from 1995 to 2013. The authors used the SWEDEHEART (Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies) register, the Swedish National Diabetes Register, and the Swedish National Patient Register to retrieve information about patient characteristics and outcomes. They estimated hazard ratios (HRs) adjusted for confounders with 95% confidence intervals (CIs) for all-cause and coronary heart disease mortality, myocardial infarction, repeat revascularization, stroke, and heart failure using inverse probability of treatment weighting based on propensity scores. RESULTS: In total, 683 patients who underwent CABG and 1,863 patients who underwent PCI were included. During a mean follow-up of 10.6 years, 53% of patients in the CABG group and 45% in the PCI group died. PCI, compared with CABG, was associated with a similar risk of all-cause mortality (HR: 1.14; 95% CI: 0.99 to 1.32), but higher risks of death from coronary heart disease (HR: 1.45; 95% CI: 1.21 to 1.74), myocardial infarction (HR: 1.47; 95% CI: 1.23 to 1.78), and repeat revascularization (HR: 5.64; 95% CI: 4.67 to 6.82). No differences in risks of stroke or heart failure were found. CONCLUSIONS: Notwithstanding the inclusion of patients with T1D who might not have been able to undergo CABG in the PCI group we found that PCI, compared with CABG, was associated with higher rates and risks of coronary heart disease mortality, myocardial infarction, and repeat revascularizations. Our findings indicate that CABG may be the preferred strategy in patients with T1D in need of multivessel revascularization.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Nyström T, Sartipy U, Franzén S, et al. PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll Cardiol. 2017. PMID: 28851544. doi:10.1016/j.jacc.2017.07.744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。